Triple G Agonists — A Home Run for Obesity?

The buzz was palpable at the 2023 American Diabetes Association Scientific Sessions as multiple new nutrient-stimulated, hormone-based therapies for obesity and type 2 diabetes took center stage. Among these therapies, the triple–hormone-receptor agonist retatrutide — the subject of a phase 2 trial by Jastreboff et al., the results of which are published in this issue of the Journal1 — showed unprecedented efficacy in treating obesity, with 24% weight loss over 48 weeks. Hormonal responses to nutrient intake are key regulators of metabolism. The best known is insulin secretion in response to postprandial increases in levels of glucose or amino acids, . . .